“…A recent meta-analysis of transapical TAVR studies revealed the following incidence of major adverse events: 30-day mortality (4.7% to 20.8%), cerebrovascular accident (0.0% to 16.3%), major tachyarrhythmia (0.0% to 48.8%), bradyarrhythmia requiring permanent pacemaker insertion (0.0% to 18.7%), cardiac tamponade (0% to 11%), major bleeding (1% to 17%), myocardial infarction (0% to 6%), aortic dissection/rupture (0% to 5%), moderate to severe paravalvular leak (0.7% to 24.0%), cardiopulmonary bypass support (0% to 15%); conversion to surgery (0.0% to 9.5%), and valve-in-valve implantation (0.6% to 8.0%) (111). Numerous studies suggest that the learning curve in this procedure may play a significant role in outcomes (47,112,113). …”